This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fichtinger-Schepman, A. M. J. Articles by Berends, F. Search for Related Content PubMed PubMed Citation Articles by Fichtinger-Schepman, A. M. J. Articles by Berends, F.

Kinetics of the Formation and Removal of Cisplatin-DNA Adducts in Blood Cells and Tumor Tissue of Cancer Patients Receiving Chemotherapy: Comparison with in Vitro Adduct Formation¹

TNO Medical Biological Laboratory, P.O. Box 45, 2280 AA Rijswijk, The Netherlands [A. M. J. F.-S., S. D. v. d. V.-V., H. C. M. v. D.-K., R. A. B., F. B.], and Department of Oncology, Antwerpen University Hospital, 2520 Edegem, Belgium [A. T. v. O.]

During chemotherapy with a cisplatin-containing combination of drugs, 217 blood samples from 30 cancer patients were analyzed for the presence of the main cisplatin-DNA adduct cis-Pt(NH₃)₂d(pGpG) (Pt-GG). Cisplatin was administered during 3-h infusions on each of 5 consecutive days, resulting in increasing adduct levels which, on the average, were about twice as high after the fifth as after the first infusion. Higher levels were found in blood samples of patients who received the same total amount of cisplatin in one single 3-h infusion. No significant differences in adduct levels were found during first and repeated courses. The nonlinear dependence of adduct levels on total dose can be attributed to removal of adducts. At 21 h after a very first cisplatin infusion 76% of the adducts were removed. Lower percentages of removal were observed over the 21-h periods following the fourth and fifth infusions of 5-day courses (49 and 53%, respectively). After the initial 21 h the removal of adducts continued, albeit at a slower rate.

Substantial interindividual variation was found in the adduct levels, which did correlate with the levels obtained after in vitro cisplatin treatment of blood samples from the same patients but not with their age or gender. Testicular cancer patients with complete tumor response showed higher adduct levels in their blood than those with partial response or progressive disease.

When blood samples from 8 healthy volunteers were treated with cisplatin in vitro, the person-to-person variation in adduct levels and the intraindividual variation observed over a 2-year period were found to be in the same range, which was narrower than that observed with samples from treated patients.

In vitro studies with human blood showed that the formation of the Pt-GG adduct is proportional to cisplatin concentration and complete after about 1 hour. In some of the in vivo and in vitro cisplatin-treated blood samples, all 4 known platinum-DNA adducts were determined. In all cases Pt-GG was by far the major adduct, and no significant differences were observed with respect to the relative amounts of the 4 adducts. Similar adduct ratios were found in DNA from a testicular tumor obtained from a patient who underwent orchidectomy; the Pt-GG adduct level was about 10-fold higher than that in his blood cells.

¹ This investigation was supported by the Dutch Cancer Society, Grant KWF-MBL 87-1.

² To whom requests for reprints should be addressed.

Received 7/ 2/90. Accepted 9/18/90.

This article has been cited by other articles:

				B. Liedert, D. Pluim, J. Schellens, and J. Thomale Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res., January 1, 2006; 34(6): e47 - e47. [Abstract] [Full Text] [PDF]

				M. A. Dimopoulos, V. L. Souliotis, A. Anagnostopoulos, C. Papadimitriou, and P. P. Sfikakis Extent of Damage and Repair in the p53 Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome J. Clin. Oncol., July 1, 2005; 23(19): 4381 - 4389. [Abstract] [Full Text] [PDF]

				V. L. Souliotis, M. A. Dimopoulos, and P. P. Sfikakis Gene-specific Formation and Repair of DNA Monoadducts and Interstrand Cross-links after Therapeutic Exposure to Nitrogen Mustards Clin. Cancer Res., October 1, 2003; 9(12): 4465 - 4474. [Abstract] [Full Text] [PDF]

				A.-K. Souid, R. L. Dubowy, S. M. Blaney, L. Hershon, J. Sullivan, W. D. McLeod, and M. L. Bernstein Phase I Clinical and Pharmacologic Study of Weekly Cisplatin and Irinotecan Combined with Amifostine for Refractory Solid Tumors Clin. Cancer Res., February 1, 2003; 9(2): 703 - 710. [Abstract] [Full Text] [PDF]

				P. D. Sadowitz, B. A. Hubbard, J. C. Dabrowiak, J. Goodisman, K. A. Tacka, M. K. Aktas, M. J. Cunningham, R. L. Dubowy, and A.-K. Souid Kinetics of Cisplatin Binding to Cellular DNA and Modulations by Thiol-Blocking Agents and Thiol Drugs Drug Metab. Dispos., February 1, 2002; 30(2): 183 - 190. [Abstract] [Full Text] [PDF]

				G. J. Veal, C. Dias, L. Price, A. Parry, J. Errington, J. Hale, A. D. J. Pearson, A. V. Boddy, D. R. Newell, and M. J. Tilby Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2205 - 2212. [Abstract] [Full Text] [PDF]